|
|
Nasdaq Gains Over 100 Points; US Consumer Sentiment Rises In November
|
|
|
|
Pasithea Therapeutics Announces Tablet PK Data From Ongoing Phase 1/1b Open-Label Study Evaluating PAS-004 In Adult Patients With Neurofibromatosis Type 1
|
|
|
|
12 Health Care Stocks Moving In Friday's Intraday Session
|
|
|
|
Dow Surges Over 200 Points; BJ's Wholesale Posts Upbeat Q3 Earnings
|
|
|
|
Pasithea Therapeutics shares are trading lower. The company announced interim Phase 1 data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, or in patients who have failed prior BRAF/MEK inhibition.
|
|
|
|
12 Health Care Stocks Moving In Friday's Pre-Market Session
|
|
|
|
Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
|
|
|
Pasithea Therapeutics shares are trading lower. The company announced interim Phase 1 data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, or in patients who have failed prior BRAF/MEK inhibition.
|
|
|
|
Pasithea Therapeutics Announces Phase 1 Data From Its Ongoing First-In-Human Trial Evaluating PAS-004; Partial Response Observed In A MEK-Rechallenge 3rd-line Melanoma Patient With Braf V600e Mutation Who Remains On Trial For More Than 11 Months; PAS-004 Has Been Well-Tolerated With All Treatment
|
|
|
|
12 Health Care Stocks Moving In Thursday's After-Market Session
|
|